Real-world Effectiveness of Sarilumab in RA: Results from the Open-label, Prospective, Single-arm Observational PROFILE Study
Abstract Introduction The 1-year PROspective sarilumab (preFILled syringe/pen) multinational, obsErvational (PROFILE) study evaluated the real-world effectiveness and safety of sarilumab in patients with moderate-to-severe rheumatoid arthritis (RA). Methods Safety endpoints included adverse events (...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2024-09-01
|
| Series: | Rheumatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40744-024-00715-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846164875129126912 |
|---|---|
| author | Alan Kivitz Jacques Eric Gottenberg Martin Bergman Chunfu Qiu Hubert van Hoogstraten Ron de Nijs Louis Bessette |
| author_facet | Alan Kivitz Jacques Eric Gottenberg Martin Bergman Chunfu Qiu Hubert van Hoogstraten Ron de Nijs Louis Bessette |
| author_sort | Alan Kivitz |
| collection | DOAJ |
| description | Abstract Introduction The 1-year PROspective sarilumab (preFILled syringe/pen) multinational, obsErvational (PROFILE) study evaluated the real-world effectiveness and safety of sarilumab in patients with moderate-to-severe rheumatoid arthritis (RA). Methods Safety endpoints included adverse events (AEs) and lab abnormalities. Effectiveness endpoints included the ACR core set. The primary endpoint was the change from baseline in Clinical Disease Activity Index (CDAI). All statistics are descriptive and p values were nominal. Results In total, 595 patients were treated, of whom 223 (37.5%) received sarilumab monotherapy and 372 (62.5%) received combination therapy. Upon initiation of sarilumab, an improvement in the mean (SD) CDAI score was observed at week 24 [11.4 (10.3)] and was maintained through week 52 [10.0 (10.5)], resulting in a mean [SD] reduction of −14.9 (12.7) and −14.4 (12.9), respectively. There were consistent improvements in disease activity that were similar for patients on monotherapy vs. combination therapy. An increase in the proportion of patients achieving remission and low disease activity was reported. By week 52, both groups had improved physical function and quality of life. There were no new safety signals. The proportions of any patients reporting a treatment-emergent adverse event (TEAE) or serious treatment-emergent AE (SAE) was 66.2% and 5.9%, respectively, and were similar between both treatment groups. Overall, 15.6% of patients discontinued sarilumab treatment due to TEAEs. The most commonly reported TEAE of interest was neutropenia (14.1%). Conclusions In this 1-year, observational real-world study, sarilumab therapy resulted in improved clinical outcomes. The safety profile was consistent with that observed in sarilumab randomized clinical trials. This study was entered on the German website (Paul Ehrlich Institute) on January 11, 2018, with NIS No.: 423. |
| format | Article |
| id | doaj-art-f98da2876c6e42148dfe1f0f8228c479 |
| institution | Kabale University |
| issn | 2198-6576 2198-6584 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Rheumatology and Therapy |
| spelling | doaj-art-f98da2876c6e42148dfe1f0f8228c4792024-11-17T12:48:20ZengAdis, Springer HealthcareRheumatology and Therapy2198-65762198-65842024-09-011161533155010.1007/s40744-024-00715-9Real-world Effectiveness of Sarilumab in RA: Results from the Open-label, Prospective, Single-arm Observational PROFILE StudyAlan Kivitz0Jacques Eric Gottenberg1Martin Bergman2Chunfu Qiu3Hubert van Hoogstraten4Ron de Nijs5Louis Bessette6Altoona Centre for Clinical ResearchDepartment of Rheumatology, Hôpitaux de HautepierreDepartment of Medicine, Drexel University College of MedicineSanofiSanofiDepartment of Rheumatology, Elkerliek HospitalDepartment of Medicine, Université LavalAbstract Introduction The 1-year PROspective sarilumab (preFILled syringe/pen) multinational, obsErvational (PROFILE) study evaluated the real-world effectiveness and safety of sarilumab in patients with moderate-to-severe rheumatoid arthritis (RA). Methods Safety endpoints included adverse events (AEs) and lab abnormalities. Effectiveness endpoints included the ACR core set. The primary endpoint was the change from baseline in Clinical Disease Activity Index (CDAI). All statistics are descriptive and p values were nominal. Results In total, 595 patients were treated, of whom 223 (37.5%) received sarilumab monotherapy and 372 (62.5%) received combination therapy. Upon initiation of sarilumab, an improvement in the mean (SD) CDAI score was observed at week 24 [11.4 (10.3)] and was maintained through week 52 [10.0 (10.5)], resulting in a mean [SD] reduction of −14.9 (12.7) and −14.4 (12.9), respectively. There were consistent improvements in disease activity that were similar for patients on monotherapy vs. combination therapy. An increase in the proportion of patients achieving remission and low disease activity was reported. By week 52, both groups had improved physical function and quality of life. There were no new safety signals. The proportions of any patients reporting a treatment-emergent adverse event (TEAE) or serious treatment-emergent AE (SAE) was 66.2% and 5.9%, respectively, and were similar between both treatment groups. Overall, 15.6% of patients discontinued sarilumab treatment due to TEAEs. The most commonly reported TEAE of interest was neutropenia (14.1%). Conclusions In this 1-year, observational real-world study, sarilumab therapy resulted in improved clinical outcomes. The safety profile was consistent with that observed in sarilumab randomized clinical trials. This study was entered on the German website (Paul Ehrlich Institute) on January 11, 2018, with NIS No.: 423.https://doi.org/10.1007/s40744-024-00715-9Antirheumatic agentsPatient-reported outcome measuresQuality of lifeReal-worldRheumatoid arthritisSarilumab |
| spellingShingle | Alan Kivitz Jacques Eric Gottenberg Martin Bergman Chunfu Qiu Hubert van Hoogstraten Ron de Nijs Louis Bessette Real-world Effectiveness of Sarilumab in RA: Results from the Open-label, Prospective, Single-arm Observational PROFILE Study Rheumatology and Therapy Antirheumatic agents Patient-reported outcome measures Quality of life Real-world Rheumatoid arthritis Sarilumab |
| title | Real-world Effectiveness of Sarilumab in RA: Results from the Open-label, Prospective, Single-arm Observational PROFILE Study |
| title_full | Real-world Effectiveness of Sarilumab in RA: Results from the Open-label, Prospective, Single-arm Observational PROFILE Study |
| title_fullStr | Real-world Effectiveness of Sarilumab in RA: Results from the Open-label, Prospective, Single-arm Observational PROFILE Study |
| title_full_unstemmed | Real-world Effectiveness of Sarilumab in RA: Results from the Open-label, Prospective, Single-arm Observational PROFILE Study |
| title_short | Real-world Effectiveness of Sarilumab in RA: Results from the Open-label, Prospective, Single-arm Observational PROFILE Study |
| title_sort | real world effectiveness of sarilumab in ra results from the open label prospective single arm observational profile study |
| topic | Antirheumatic agents Patient-reported outcome measures Quality of life Real-world Rheumatoid arthritis Sarilumab |
| url | https://doi.org/10.1007/s40744-024-00715-9 |
| work_keys_str_mv | AT alankivitz realworldeffectivenessofsarilumabinraresultsfromtheopenlabelprospectivesinglearmobservationalprofilestudy AT jacquesericgottenberg realworldeffectivenessofsarilumabinraresultsfromtheopenlabelprospectivesinglearmobservationalprofilestudy AT martinbergman realworldeffectivenessofsarilumabinraresultsfromtheopenlabelprospectivesinglearmobservationalprofilestudy AT chunfuqiu realworldeffectivenessofsarilumabinraresultsfromtheopenlabelprospectivesinglearmobservationalprofilestudy AT hubertvanhoogstraten realworldeffectivenessofsarilumabinraresultsfromtheopenlabelprospectivesinglearmobservationalprofilestudy AT rondenijs realworldeffectivenessofsarilumabinraresultsfromtheopenlabelprospectivesinglearmobservationalprofilestudy AT louisbessette realworldeffectivenessofsarilumabinraresultsfromtheopenlabelprospectivesinglearmobservationalprofilestudy |